BioLife Solutions, Inc.
NASDAQ:BLFSMedical - Instruments & Supplies
+$0.40 today
- Market cap
- $1.89B
- Beta
- 1.97
- P/E (TTM)
- -119.9
- EPS (TTM)
- -$0.22
Volume 4.39M
Average 0.52M
BLFS EBITDA Margin
EBITDA as a percentage of revenue.
BioLife Solutions, Inc.NASDAQ: BLFS
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 2.6%
EBITDA Margin was 2.6% in Q1 FY2026, up 1.9 pp from a year earlier. On a trailing-twelve-month basis it was -7.5%, down 19.9 pp year over year. Over 3 fiscal years it widened by 166.6 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 36.0% for the fiscal year ending Dec 2026, up from 3.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 2.6%-23.4 pp QoQ
- Last fiscal yearDec 2025
- 3.7%+1.9 pp YoY
- LTMMar 2026
- -7.5%-19.9 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 3.7%
- Year-over-year change
- +1.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.7% | +1.9pp |
| FY2024 | 2024-12-31 | 1.9% | +61.5pp |
| FY2023 | 2023-12-31 | -59.6% | +103.2pp |
| FY2022 | 2022-12-31 | -162.9% | -148.9pp |
| FY2021 | 2021-12-31 | -14.0% | — |
EBITDA Margin vs competitors
How BLFS compares with its peers on the latest reported figures
- BLFS's LTM Mar 2026 EBITDA Margin of -7.5% is the 7th highest of the 11 companies compared; the peer median is -2.7%.
- Its year-over-year change of -19.9 pp is the 8th highest of 10, against a peer median of +8.5 pp.
- Over three fiscal years its change of +166.6 pp compares with a peer median of +3.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 11.9% | +111.0 pp | +3.8 pp | |
| LTM Mar 2026 | 11.7% | +3.4 pp | +19.6 pp | |
| LTM Apr 2026 | 8.6% | +10.7 pp | +57.9 pp | |
| LTM Jun 2026 | 6.6% | +8.5 pp | +12.0 pp | |
| LTM Apr 2026 | -1.4% | +10.6 pp | -48.3 pp | |
| LTM Sep 2026 | -4.0% | +21.1 pp | +24.5 pp | |
| LTM Mar 2026 | -7.5% | -19.9 pp | +166.6 pp | |
| LTM Sep 2026 | -15.2% | -24.8 pp | -32.6 pp | |
| LTM Mar 2026 | -23.0% | -10.7 pp | -5.5 pp | |
| LTM Jan 2026 | -152.9% | -23.0 pp | — | |
| LTM Jun 2026 | -6717.4% | — | -12324.3 pp | |
| Peer median (excluding BLFS) | -2.7% | +8.5 pp | +3.8 pp | |
Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 119.16M | 76.24M | 75.86M | 82.25M | 96.21M |
| Cost of Revenue | 90.31M | 29.33M | 96.52M | 28.58M | 34.1M |
| Gross Profit | 28.85M | 46.91M | 46.75M | 53.67M | 62.12M |
| Gross Margin | 24.2% | 61.5% | 61.6% | 65.3% | 64.6% |
| Research & Development | 11.82M | 14.8M | 18.8M | 7.91M | 7.57M |
| Selling, General & Admin | 48.09M | 44.93M | 55.97M | 50.15M | 55.37M |
| Operating Expenses | 73.34M | 52.83M | 117.58M | 60.8M | 74.25M |
| Depreciation & Amortization | 12.87M | 19.96M | 12.3M | 8.66M | 4.69M |
| EBITDA | (16.65M) | (124.18M) | (45.24M) | 1.53M | 3.61M |
| EBITDA Margin | -14.0% | -162.9% | -59.6% | 1.9% | 3.7% |
| Operating Income | (35.16M) | (5.92M) | (23.44M) | (7.13M) | (1.08M) |
| Operating Margin | -29.5% | -7.8% | -30.9% | -8.7% | -1.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 485K | 687K | 1.81M | 719K | 2.71M |
| Other Income / Expenses | 6.13M | 1.08M | 4.97M | (4.3M) | (11M) |
| Income Before Tax | (29.03M) | (4.85M) | (18.47M) | (11.43M) | (12.08M) |
| Pre-Tax Margin | -24.4% | -6.4% | -24.4% | -13.9% | -12.6% |
| Income Tax Expense | (20.12M) | (5.24M) | 24K | (38K) | 49K |
| Net Income | (8.91M) | (139.81M) | (66.43M) | (20.18M) | (12.13M) |
| Net Margin | -7.5% | -183.4% | -87.6% | -24.5% | -12.6% |
| EPS (Basic) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| EPS (Diluted) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| Weighted Avg Shares | 38.5M | 42.48M | 43.72M | 46.07M | 47.75M |
| Weighted Avg Shares (Diluted) | 38.5M | 42.48M | 43.72M | 46.07M | 48.65M |
BioLife Solutions, Inc.
NASDAQ:BLFS
Intrinsic Alpha fair value
Locked
Current Price
$38.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.